Results 11 to 20 of about 11,222 (199)

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study) [PDF]

open access: yes, 2016
Background: Tiotropium + olodaterol has demonstrated improvements beyond lung function benefits in a large Phase III clinical program as a once-daily maintenance treatment for COPD and may be a potential option for the initiation of maintenance treatment
Beeh, Kai-Michael   +8 more
core   +2 more sources

Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases [PDF]

open access: yes, 2004
Fluticasone propionate - the first carbothioate corticosteroid - has been classified as a potent anti-inflammatory drug for dermatological use. It is available as 0.05% cream and 0.005% ointment formulations for the acute and maintenance treatment of ...
Atsuta J   +33 more
core   +1 more source

Inhaled corticosteroids versus long-acting beta -agonists for chronic obstructive pulmonary disease (Review). [PDF]

open access: yes, 2011
Long-acting beta(2)-agonists and inhaled corticosteroids can be used as maintenance therapy by patients with moderate to severe chronic obstructive pulmonary disease. These interventions are often taken together in a combination inhaler.
Agarwal   +105 more
core   +2 more sources

The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy

open access: yesBMC Nephrology, 2023
Background Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulopathy worldwide, and lacks the effective treatment. The study was aimed to investigate the clinical efficacy of fluticasone propionate aerosol combined with angiotensin ...
Liping Sun   +3 more
doaj   +1 more source

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. [PDF]

open access: yes, 2014
BACKGROUND: Inhaled corticosteroids (ICS) are anti-inflammatory drugs that have proven benefits for people with worsening symptoms of chronic obstructive pulmonary disease (COPD) and repeated exacerbations.
Agarwal   +163 more
core   +1 more source

Investigating the suitability of high content image analysis as a tool to assess the reversibility of foamy alveolar macrophage phenotypes in vitro. [PDF]

open access: yes, 2020
Many potential inhaled medicines fail during development due to the induction of a highly vacuolated or “foamy” alveolar macrophage phenotype response in pre-clinical studies.
Hoffman, Ewelina   +2 more
core   +2 more sources

Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma [PDF]

open access: yes, 2011
Asthma patients who continue to experience symptoms despite being on regular inhaled corticosteroids (ICS) represent a management challenge. Long-acting beta2-agonists (LABA) or anti-leukotrienes (LTRA) are two treatment options that could be considered ...
Adams   +207 more
core   +1 more source

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events [PDF]

open access: yes, 2010
Background An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews.
Aalbers   +27 more
core   +2 more sources

A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis [PDF]

open access: yes, 2016
Background: Corticosteroid nasal sprays are the mainstay of treatment for allergic rhinitis. These sprays have sensory attributes such as scent and/or odor, taste and aftertaste, and run down the throat and/or the nose, which, when unpleasant, can affect
Bremner, P   +6 more
core   +2 more sources

Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease [PDF]

open access: yes, 2010
Background Combination therapy (inhaled corticosteroids and long-acting beta(2)-agonists) and tiotropium are both used in the treatment of chronic obstructive pulmonary disease (COPD).
Appleton   +20 more
core   +1 more source

Home - About - Disclaimer - Privacy